The University of Chicago Header Logo

Connection

Peter H. O'Donnell to Immunohistochemistry

This is a "connection" page, showing publications Peter H. O'Donnell has written about Immunohistochemistry.
Connection Strength

0.026
  1. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016 09 10; 34(26):3119-25.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.